logo-loader
viewShield Therapeutics PLC

Shield Therapeutics 'in a strong position' and confident of a US Feraccru deal

Shield Therapeutics (LON:STX) chief financial officer Tim Watts talks Proactive London's Andrew Scott through their first half update to June 2019.

''If you consider where we've been over the last 12 months we're in a far, far stronger position now and with the US approval of Feraccru we're in a good place''.

''We have to convert that into a deal but we believe we have every prospect of doing that''.

''The approval in the US is great ...it should be extremely attractive to a significant number of partners and gives us a great deal of confidence that we can get a deal done''.

Quick facts: Shield Therapeutics PLC

Price: 185.4 GBX

LSE:STX
Market: LSE
Market Cap: £217.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield's Feraccru likely to command 'high market share and branded pricing'

Capital Network analyst Emma Ulker assesses recent progress made at Shield Therapeutics PLC (LON:STX) with its lead asset Feraccru. The drug's approved and marketed in Europe, with a US approval decision pending for July 27. Feraccru is an oral product absorbed in the gut. It's also...

on 11/5/19

2 min read